Low dose fluorometholone stops endothelial rejection after PKP

Article

Using 0.1% fluorometholone after penetrating keratoplasty (PKP) significantly reduces the chances of endothelial rejection.

Using 0.1% fluorometholone after penetrating keratoplasty (PKP) significantly reduces the chances of endothelial rejection, claims a study in Ophthalmology.

A randomized, non-blinded, clinical trial, led by Dr Jun Shimazaki, Department of Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan, included 42 patients who underwent PKP. Each patient had been administered topical steroid eye drops and maintained graft clarity for over one year.

The participants were randomly assigned to two groups and were assessed for 12 months. Group was administered 0.1% of fluorometholone three times daily and group 2 were not administered any steroids.

In group 1 there were 17 patients who completed the trial and in group 2 there were 15 patients. Endothelial rejection was developed in 1 patient in group 1 and 6 patients in group 2 at an average of 5.2±4.5 after PKP.

There were no differences in visual acuity, intraocular pressure, epithelial damage, tear film break-up time, cataract progression, infection, or incidence of systemic side effects between the groups.

There were no adverse effects reported when using 0.1% fluorometholone and the study suggests using low dose corticosteroids even in low-risk cases.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.